Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03872791 | A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast Cancer | completed | Phase 1 / Phase 2 | 52 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Jun 8, 2023 | clinicaltrials |
| NCT05727098 | Dexmedetomedine and Ketamine in Erector Spinae Block for Postoperative Analgesia Following Mastectomy. | completed | Phase 2 / Phase 3 | 75 | National Cancer Institute, EgyptOTHER | 1 | Jun 8, 2023 |
| clinicaltrials |
| NCT00002826 | Drug Resistance Inhibition in Treating Women With Recurrent or Metastatic Breast Cancer | completed | Phase 2 | 36 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 7, 2023 | clinicaltrials |
| NCT02768701 | Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer | completed | Phase 2 | 40 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT00921115 | Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer. | completed | Phase 2 | 42 | University of Kansas Medical CenterOTHER | 1 | May 19, 2023 | clinicaltrials |
| NCT02526498 | Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery(TRIUMPH-T) | completed | Phase 2 | 200 | Rutgers, The State University of New JerseyOTHER | 1 | May 15, 2023 | clinicaltrials |
| NCT03988036 | A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1)(Keyriched-1) | completed | Phase 2 | 46 | Women's Cancer Study Group GmbHOTHER | 1 | May 15, 2023 | clinicaltrials |
| NCT04752059 | Phase II Study of T-DX in HER2-positive Breast Cancer Brain Metastases(TUXEDO-1) | completed | Phase 2 | 15 | Medical University of ViennaOTHER | 1 | May 12, 2023 | clinicaltrials |
| NCT02408770 | Breast Cancer - Anti-Progestin Prevention Study 1(BC-APPS1) | completed | Phase 2 | 24 | Manchester University NHS Foundation TrustOTHER_GOV | 1 | May 6, 2023 | clinicaltrials |
| NCT02891759 | Compare Outcomes Between Two Acellular Dermal Matrices | completed | Phase 2 | 320 | Washington University School of MedicineOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT01698918 | Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer(BOLERO-4) | completed | Phase 2 | 202 | Novartis PharmaceuticalsINDUSTRY | 13 | May 3, 2023 | clinicaltrials |
| NCT03321929 | Intraoperative Detection of Residual Cancer in Breast Cancer | completed | Phase 2 | 234 | Lumicell, Inc.INDUSTRY | 1 | May 1, 2023 | clinicaltrials |
| NCT00337649 | A Study of Epothilone D in Combination With Herceptin (Trastuzumab) in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 27 | Hoffmann-La RocheINDUSTRY | 1 | Apr 28, 2023 | clinicaltrials |
| NCT00881361 | Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes After Chemotherapy in Treating Women With Stage II, Stage IIIA, or Stage IIIB Breast Cancer | completed | Phase 2 | 756 | Alliance for Clinical Trials in OncologyOTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT01417286 | Accelerated Radiation Therapy After Surgery in Treating Patients With Breast Cancer | completed | Phase 2 | 69 | Rutgers, The State University of New JerseyOTHER | 1 | Apr 20, 2023 | clinicaltrials |
| NCT03112590 | Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer | completed | Phase 1 / Phase 2 | 51 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT01922921 | Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy | completed | Phase 1 / Phase 2 | 31 | University of WashingtonOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05812326 | PD-1 Knockout Anti-MUC1 CAR-T Cells in the Treatment of Advanced Breast Cancer | completed | Phase 1 / Phase 2 | 15 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Apr 13, 2023 | clinicaltrials |
| NCT03564171 | Prehabilitation for Women Undergoing Pre-operative Chemotherapy for Breast Cancer | completed | Phase 2 / Phase 3 | 63 | Sunnybrook Health Sciences CentreOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT04836520 | SHR6390 Combined With Anastrozole for Preoperative Treatment of Breast Cancer. | completed | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT00258960 | Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer | completed | Phase 2 | 49 | Spanish Breast Cancer Research GroupOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT00432172 | Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients | completed | Phase 2 | 189 | Spanish Breast Cancer Research GroupOTHER | 1 | Apr 3, 2023 | clinicaltrials |
| NCT03025880 | Trial to Evaluate Efficacy and Safety of Pembrolizumab and Gemcitabine in HER2-negative ABC(PANGEA) | completed | Phase 2 | 36 | Spanish Breast Cancer Research GroupOTHER | 1 | Apr 3, 2023 | clinicaltrials |
| NCT00841828 | Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients | completed | Phase 2 | 102 | Spanish Breast Cancer Research GroupOTHER | 1 | Mar 31, 2023 | clinicaltrials |
| NCT01036087 | Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer | completed | Phase 2 | 47 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT01306942 | Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients | completed | Phase 1 / Phase 2 | 37 | Spanish Breast Cancer Research GroupOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT01565499 | Neoadjuvant Treatment With Nab-paclitaxel for Patients With Stage II and III Luminal Breast Cancer | completed | Phase 2 | 83 | Spanish Breast Cancer Research GroupOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT05298696 | Efficacy of Cilostazol in Prevention of Peripheral Neuropathy | completed | Phase 1 / Phase 2 | 71 | Mansoura UniversityOTHER | 1 | Mar 15, 2023 | clinicaltrials |
| NCT02894398 | Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant(INGE-B) | completed | Phase 2 | 388 | iOMEDICO AGINDUSTRY | 1 | Mar 13, 2023 | clinicaltrials |
| NCT02983045 | A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors(PIVOT-02) | completed | Phase 1 / Phase 2 | 557 | Nektar TherapeuticsINDUSTRY | 8 | Mar 13, 2023 | clinicaltrials |
| NCT05351021 | Efficacy of Metformin as Preventive Treatment in Paclitaxel Induced Peripheral Neuropathy in Breast Cancer Patients | completed | Phase 2 | 76 | Mansoura UniversityOTHER | 1 | Mar 9, 2023 | clinicaltrials |
| NCT00128843 | Exemestane Versus Anastrozole as First Line Hormone Therapy in Postmenopausal Metastatic Breast Cancer Patients | completed | Phase 2 | 103 | Spanish Breast Cancer Research GroupOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT00128856 | Gemcitabine, Doxorubicin and Paclitaxel (GAT) as Neoadjuvant Treatment of Breast Cancer Patients | completed | Phase 2 | 46 | Spanish Breast Cancer Research GroupOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT00129896 | Neoadjuvant Chemotherapy With Myocet/Taxotere/Herceptin for HER2 Positive Breast Cancer Patients | completed | Phase 1 / Phase 2 | 73 | Spanish Breast Cancer Research GroupOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT04477616 | Injection Regimen Trial of PEG-rhG-CSF During Breast Cancer Chemotherapy | completed | Phase 2 | 160 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 23, 2023 | clinicaltrials |
| NCT02314156 | Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy | completed | Phase 2 | 67 | Northwestern UniversityOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT02479997 | Clinical Application of Dual Sentinel Lymph Node Staining Method in Breast Cancer Patients | completed | Phase 2 | 130 | National Cancer Center, KoreaOTHER_GOV | 1 | Feb 22, 2023 | clinicaltrials |
| NCT02401347 | Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors | completed | Phase 2 | 21 | Melinda TelliOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT04320030 | [18F]-DPA-714 PET/CT (Positron Emission Tomography/Computerized Tomography) in Triple Negative Breast Cancers(EITHICS) | completed | Phase 2 | 13 | Institut Cancerologie de l'OuestOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT04366713 | A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib | completed | Phase 2 | 6 | Puma Biotechnology, Inc.INDUSTRY | 1 | Feb 10, 2023 | clinicaltrials |
| NCT00608972 | Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer | completed | Phase 2 | 31 | Rutgers, The State University of New JerseyOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT02049957 | Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer | completed | Phase 2 | 118 | Calithera Biosciences, IncINDUSTRY | 3 | Feb 8, 2023 | clinicaltrials |
| NCT02756364 | Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy | completed | Phase 2 | 141 | Calithera Biosciences, IncINDUSTRY | 2 | Feb 8, 2023 | clinicaltrials |
| NCT03732391 | Phase 2 Study of Pembrolizumab+Carboplatin in Breast Related Cancer Antigens-related Metastatic Breast Cancer (PEMBRACA) | completed | Phase 2 | 22 | CORTESI LAURAOTHER | 1 | Jan 31, 2023 | clinicaltrials |
| NCT03499899 | A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer | completed | Phase 2 | 88 | Novartis PharmaceuticalsINDUSTRY | 17 | Jan 30, 2023 | clinicaltrials |
| NCT02236000 | A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer | completed | Phase 1 / Phase 2 | 49 | NSABP Foundation IncNETWORK | 1 | Jan 26, 2023 | clinicaltrials |
| NCT01446016 | Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer After Anthracycline Failure (CAT)(CAT) | completed | Phase 2 | 38 | The Methodist Hospital Research InstituteOTHER | 1 | Jan 23, 2023 | clinicaltrials |
| NCT02652923 | Contrast Ultrasound Detection of Sentinel Lymph Nodes | completed | Phase 1 / Phase 2 | 98 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Jan 23, 2023 | clinicaltrials |
| NCT03430479 | Anti PD-1 Antibody With Radiation Therapy in Patients With HER2-negative Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 32 | Kyoto Breast Cancer Research NetworkOTHER | 1 | Jan 19, 2023 | clinicaltrials |
Data updated 24 days agoSource updated Jun 8, 2023source: clinicaltrials